ライフサイエンスコーパス: papillary thyroid cancer

1 eptor kinase that undergoes rearrangement in papillary thyroid cancer).

2 ancer, and 29 with the follicular variant of papillary thyroid cancer).

3 ay result in a transient increase in risk of papillary thyroid cancer.

4 st 4 decades, driven largely by increases in papillary thyroid cancer.

5 acy of its mortality risk classification for papillary thyroid cancer.

6 to the presence of BRAF(V600E) mutations in papillary thyroid cancer.

7 idectomy vs lobectomy to treat patients with papillary thyroid cancer.

8 vertreatment of thyroid nodules and low-risk papillary thyroid cancer.

9 ve of disease-free survival in patients with papillary thyroid cancer.

10 ina participating in a case-control study on papillary thyroid cancer.

11 r (95% CI, 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

12 oid cancer mortality rate for advanced-stage papillary thyroid cancer.

13 afenib in patients with BRAF(V600E)-positive papillary thyroid cancer.

14 The most frequent association is noted with papillary thyroid cancer.

15 od markedly increases the risk of developing papillary thyroid cancer.

16 ificance of Delphian node (DN) metastasis in papillary thyroid cancer.

17 istent disease in patients with conventional papillary thyroid cancer.

18 istent disease in patients with conventional papillary thyroid cancer.

19 utation is primarily present in conventional papillary thyroid cancer.

20 al rearrangements in a majority of childhood papillary thyroid cancers.

21 cancer syndrome with colorectal, breast and papillary thyroid cancers.

22 en by increased detection of small, indolent papillary thyroid cancers.

23 ary thyroid cancers (MTC) and of a subset of papillary thyroid cancers.

24 e, 3 (20%) were malignant, all of which were papillary thyroid cancers.

25 e lesions were malignant, the majority being papillary thyroid cancers.

26 action and found frequent CpG methylation in papillary thyroid cancer (23 of 39 patients; 59%) and fo

27 cancer (51.0%) than in follicular variant of papillary thyroid cancer (24.1%) and follicular thyroid

28 AF V600E mutation was higher in conventional papillary thyroid cancer (51.0%) than in follicular vari

29 s, 46% of follicular thyroid cancers, 71% of papillary thyroid cancers, 71% of anaplastic thyroid can

30 s with thyroid cancer (245 with conventional papillary thyroid cancer, 73 with follicular thyroid can

31 Papillary thyroid cancer accounts for approximately 84%

32 ne (BRAF V600E), which is primarily found in papillary thyroid cancer and is associated with more agg

33 Among 451 incident cases of papillary thyroid cancer and matched controls (median ag

34 's thyroiditis is frequently associated with papillary thyroid cancer and may indeed be a risk factor

35 s-sectional study, individuals with low-risk papillary thyroid cancer and solitary kidney masses were

36 ns of BRAF are found in approximately 45% of papillary thyroid cancers and are enriched in tumors wit

37 urgeons and pathologists in the treatment of papillary thyroid cancer, and especially intermediate-ri

38 erwent thyroid surgery from 2007 to 2009 for papillary thyroid cancer, and had their DN harvested ab

39 mutation in BRAF causes malignant melanoma, papillary thyroid cancer, and other malignancies.

40 010-2013), primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [9

41 Women with papillary thyroid cancer are at increased risk of in sit

42 l disease risk in patients after surgery for papillary thyroid cancer as a function of primary tumor

43 Four of the lesions were found to be papillary thyroid cancers at fine-needle aspiration biop

44 -based cohort of 10,932 women diagnosed with papillary thyroid cancer between 1988 and 1999.

45 Using patients who were treated for papillary thyroid cancer between January 1979, to July 2

46 In patients with conventional papillary thyroid cancer, BRAF V600E mutation was associ

47 tor antagonism, chemical concentrations, and papillary thyroid cancer case status.

48 overshadowed by its more common counterpart-papillary thyroid cancer-despite its unique biological b

49 that prophylactic CLND may be performed for papillary thyroid cancer, especially for advanced tumors

50 Papillary thyroid cancers exhibit a marked increase in s

51 In conclusion, papillary thyroid cancers exhibit specific patterns of a

52 nd/or CT in individuals with treatment-naive papillary thyroid cancer for CLNM and/or extrathyroidal

53 tinct foci of well-differentiated multifocal papillary thyroid cancer from 17 women.

54 unclear whether the increasing incidence of papillary thyroid cancer has been related to thyroid can

55 B-type RAF kinase mutations in papillary thyroid cancer have been found to be associate

56 About half of patients with papillary thyroid cancer have tumours with activating BR

57 ing for an 11-y-old girl with differentiated papillary thyroid cancer, heavy lung involvement, and ce

58 significantly increase mortality in stage IV papillary thyroid cancer (HR 2.75 [1.36-5.58], p=0.0049)

59 ho were aged 18-64 years when diagnosed with papillary thyroid cancer in 1988-1994 and 574 controls t

60 in three patients with BRAF(V600E)-positive papillary thyroid cancer in a phase 1 trial.

61 Papillary thyroid cancer incidence increased for all SEE

62 he key role of TSH signaling in Braf-induced papillary thyroid cancer initiation and provide experime

63 ional imaging for preoperative evaluation of papillary thyroid cancer is debated.

64 ultiple cancers; the AJCC classification for papillary thyroid cancer is solely based on clinical par

65 The gene (or genes) for familial papillary thyroid cancer is yet to be identified, wherea

66 The adequacy of unilateral surgery for papillary thyroid cancers is controversial.

67 ed in G(1) arrest in two well differentiated papillary thyroid cancer lines (PTCs) and both G(1) arre

68 In 105 patients with papillary thyroid cancer (median [IQR] follow-up, 3.8 [3

69 of a cohort of 262 patients (66% women, 93% papillary thyroid cancer; median dose, 5,217 MBq [141 mC

70 ts, and subgroup analyses were performed for papillary thyroid cancer (n = 341) and follicular thyroi

71 g the kinase domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, an

72 noted in a gastrointestinal stromal tumour, papillary thyroid cancers, non-small-cell lung cancer, o

73 idual tumor foci in patients with multifocal papillary thyroid cancer often arise as independent tumo

74 The ret/ptc2 papillary thyroid cancer oncogene, an oncogenic form of

75 e deficiency, PTEN, hereditary papillary RC, Papillary thyroid cancer- Papillary RC, Hereditary leiom

76 All papillary thyroid cancer patients with tumor size of 1 c

77 a from the largest subgroup, that is, female papillary thyroid cancer patients.

78 Occult and manifest papillary thyroid cancers present at about the same time

79 Patients with papillary thyroid cancers presenting as occult papillary

80 ifferentiated thyroid cancer (DTC), that is, papillary thyroid cancer (PTC) and follicular thyroid ca

81 2017, 90% of thyroid cancers diagnosed were papillary thyroid cancer (PTC) and in 2013 to 2017, the

82 mutated gene in malignant melanoma (MM) and papillary thyroid cancer (PTC) and is causally involved

83 d most frequent target region for metastatic papillary thyroid cancer (PTC) and medullary thyroid can

84 C) cells were derived from a small subset of papillary thyroid cancer (PTC) cells.

85 PURPOSE OF REVIEW: Aggressive variants of papillary thyroid cancer (PTC) have been recognized with

86 d to clarify whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival

87 t recommendation for pediatric patients with papillary thyroid cancer (PTC) is a total thyroidectomy.

88 ctive iodine (RAI) treatment for early-stage papillary thyroid cancer (PTC) is complex because of unc

89 The incidence of human papillary thyroid cancer (PTC) is increasing and an aggr

90 Papillary thyroid cancer (PTC) is the most common endocr

91 Papillary thyroid cancer (PTC) is the most common type o

92 SUV(max) and gene expression profiles in 80 papillary thyroid cancer (PTC) patients.

93 Papillary thyroid cancer (PTC) rates continue to increas

94 shown to be highly associated with increased papillary thyroid cancer (PTC) risk with an odds ratio o

95 leotide polymorphisms (SNPs) associated with papillary thyroid cancer (PTC) risk.

96 biology in RAI-refractory BRAF(V600E)-mutant papillary thyroid cancer (PTC) to selectively drive NIS

97 Papillary thyroid cancer (PTC) was diagnosed in 97% of p

98 d O-GlcNAcylation (O-GlcNAc) modification in papillary thyroid cancer (PTC) were essential in tumor g

99 lysed a multi-generation CS-like family with papillary thyroid cancer (PTC), applying a combined link

100 BRAF V600E is a prominent oncogene in papillary thyroid cancer (PTC), but its role in PTC-rela

101 ty risk factor in the risk stratification of papillary thyroid cancer (PTC), but whether this is gene

102 vascular endothelial growth factor (VEGF) in papillary thyroid cancer (PTC), we conducted a phase II

103 nsidered to play a unique prognostic role in papillary thyroid cancer (PTC), with a distinct staging

104 patients with clinically node negative (cN0) papillary thyroid cancer (PTC).

105 RET gene are common in radiation-associated papillary thyroid cancer (PTC).

106 r optimizing (131)I therapy in patients with papillary thyroid cancer (PTC).

107 erienced by individuals newly diagnosed with papillary thyroid cancer (PTC).

108 on of a murine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

109 ells (MSCs) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

110 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

111 E and TERT promoter mutations can coexist in papillary thyroid cancer (PTC).

112 mens for preoperative risk stratification in papillary thyroid cancer (PTC).

113 only in patients age 45 years or older with papillary thyroid cancer (PTC); patients younger than ag

114 rs including 15 follicular adenomas (FA), 13 papillary thyroid cancers (PTC) and 14 follicular thyroi

115 Papillary thyroid cancers (PTC) are associated with nono

116 A control cohort of 447 sporadic papillary thyroid cancers (PTC) from The Cancer Genome A

117 The extent of surgery for papillary thyroid cancers (PTC) remains controversial.

118 ten (Braf(V600E)/Pten(-/-)/TPO-Cre) leads to papillary thyroid cancers (PTC) that rapidly progress to

119 E) mutation is found in approximately 40% of papillary thyroid cancers (PTC).

120 he Cancer Genome Atlas study (TCGA study) of papillary thyroid cancers (PTC).

121 pression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTCs) that are locally invasi

122 positive tumors, including MNG, schwannomas, papillary thyroid cancers (PTCs), and Wilms tumors.

123 id adenomas, follicular thyroid cancers, and papillary thyroid cancers (PTCs).

124 ter methylation of tumor suppressor genes in papillary thyroid cancer, RASSF1A and SLC5A8, was achiev

125 ients with progressive, BRAF(V600E)-positive papillary thyroid cancer refractory to radioactive iodin

126 ologically confirmed recurrent or metastatic papillary thyroid cancer refractory to radioactive iodin

127 thyroid cancer diagnosis was associated with papillary thyroid cancer risk.

128 ehensive multiplatform analysis of 496 adult papillary thyroid cancer samples reported by The Cancer

129 Papillary thyroid cancer-specific mortality for cases wi

130 relationship between the genetic status and papillary thyroid cancer-specific mortality for each of

131 Papillary thyroid cancer-specific mortality occurred in

132 Results: Papillary thyroid cancer-specific mortality occurred in

133 The primary endpoint was papillary thyroid cancer-specific mortality, characteris

134 ncluding undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammat

135 Two individuals had papillary thyroid cancers (stage II and stage III) and o

136 her study is warranted of the role of CT for papillary thyroid cancer staging, possibly as an adjunct

137 ent, and a long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTC

138 lexity was observed from well-differentiated papillary thyroid cancer to poorly differentiated and an

139 sence of MSCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracr

140 surgical or cytological specimens of primary papillary thyroid cancer tumours at each centre.

141 iagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic

142 oidectomy and sentinel lymph node biopsy for papillary thyroid cancer were accrued.

143 attributable to an increase in incidence of papillary thyroid cancer, which increased from 2.7 to 7.

144 buted to overdiagnosis of small and indolent papillary thyroid cancers, which has largely been driven

145 en countries for patients (of all ages) with papillary thyroid cancer who had been surgically treated

146 Methods: We included 38 patients with papillary thyroid cancer who underwent radioiodine imagi

147 t patients diagnosed with localized >/= 1-cm papillary thyroid cancer who underwent thyroidectomy wit

148 Patients who undergo surgery for papillary thyroid cancer with only a limited lymph node

149 hyroiditis report an increased prevalence of papillary thyroid cancer, with a favorable disease profi